Ongentys will be reimbursed upon accepting the committee

Only the CMV treatment Prevymis passed

SK Chemicals' new drug 'Ongentys (Opicapone)', which is a new treatment for Parkinson's disease, ,accepts below the evaluation amount of the Pharmaceutical Benefits Advisory Committee the reimbursed price will likely pass.

 

The HIRA (President Seon-min Kim) released the results of the deliberation on the adequacy of the medical care benefits of the decision-making drug that was deliberated by the 5th Pharmaceutical Benefits Advisory Committee on the 8th.

 

The only drug that has been evaluated for reimbursed adequacy at this time is MSD Korea's CMV infection treatment, 'Prevymis (Letermovir) 250mg and 480mg'.

 

Prevymis, a drug that prevents giant cell virus infection in hematopoietic stem cell transplant patients, has been approved for use in the prevention of CMV infection and disease in adult patients who have undergone allogeneic hematopoietic stem cell transplant (HSCT) from the MFDS in 2018.

 

The U.S.

 

permit was in 2017, and the FDA has also designated Prevymis as a breakthrough therapy, a priority review drug, and a fast track drug.

 

Ongentys 50mg deliberated by the committee and the ovarian stimulant 'Rekovelle Prefilled Pen (Follitropin delta)', which is a controlled ovarian stimulant in women receiving supplementary reproductive therapy from Ferring Pharmaceuticals, has a reasonable reimbursement, but the amount requested by the pharmaceutical company is high.

 

Ongentys is a standard treatment for Levodopa/Dopa decarboxylase inhibitor (DDCI), and is an adjunct to Levodopa/Dopa decarboxylase inhibitor (DDCI) in patients with Parkinson's syndrome with symptoms of motor agitation, which do not improve symptoms.

 

It was approved in Korea on November 26, last year.

 

Rekovelle Prefilled Pen received domestic approval as an indication for controlled ovarian stimulation to mature multiple follicles in women receiving adjuvant reproductive procedures, such as in vitro fertilization or intracellular sperm injection, on December 27 last year.

 

The HIRA said that Ongentys and Rekovelle Prefilled Pen are recognized for the appropriateness of the reimbursement when they are accepted below the evaluation amount.

 

However, if the pharmaceutical company does not accept it, non-reimbursement price will be continued.

 

On the other hand, in accordance with Article 11-2 of the Rules on the Regulation for Criteria for Providing Reimbursed services in the NHI, the HIRA evaluates the adequacy of pharmaceuticals through the deliberation of the Pharmaceutical Benefits Advisory Committee.

 

The final evaluation result can be changed if changes in details of the scope of the drug and the standard items of the drug, changes in the permission of the item requested for decision, and withdrawal of the permission.